COVID-19 trials registries data warehouse

https://clinicaltrials.gov/show/NCT04338828

N. Stuart Harris, MD, MFA

nsharris@mgh.harvard.edu

2020-04-08

Terminated

RCT

Randomized

Parallel

Blind label

single-center

Treatment

inclusion criteria: age ≥ 18 years old presentation to the ed with respiratory symptoms likely caused by covid-19 patient displays at least one of the following respiratory rate ≥ 24 new cough new atypical chest pain new dyspnea oxygen saturation < 97% at rest chest x-ray with new changes consistent with covid-related airspace disease cleared for discharge home by attending physician obtained covid testing (results not required at time of enrollment) onset of symptoms ≤12 days prior to ed visit

- attending physician estimation (< 50% likelihood) of other more likely non-covid etiology - presence of tracheostomy - requirement of oxygen therapy to maintain resting oxygen saturation of > 94% - clinical contraindication to use of inhaled nitric oxide

2

Massachusetts General Hospital

18

None

United States

Mild disease at enrollment

1: Mild disease at enrollment

47

Rates of return visits to the ED

None

Phase 2

[{"arm_notes": "", "treatment_id": 890, "treatment_name": "Nitric oxide gas", "treatment_type": "Gas inhalation", "pharmacological_treatment": "Non pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2188, "treatment_name": "Standard of care", "treatment_type": "Standard of care", "pharmacological_treatment": "Standard of care"}]